Verastem, Inc. (LON:0LOV)
London
· Delayed Price · Currency is GBP · Price in USD 4.885
-0.010 (-0.20%)
At close: Jul 15, 2025
Verastem Revenue
Verastem had revenue of $10.00M USD in the twelve months ending March 31, 2025. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue
$10.00M
Revenue Growth
n/a
P/S Ratio
25.92
Revenue / Employee
$128.21K
Employees
78
Market Cap
200.62M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Verastem News
- 19 days ago - Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha
- 21 days ago - Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Business Wire
- 6 weeks ago - What's Going On With Verastem Oncology Stock On Monday? - Benzinga
- 6 weeks ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - Business Wire
- 6 weeks ago - Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
- 7 weeks ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - Business Wire
- 2 months ago - Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
- 2 months ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire